GF Fund Management CO. LTD. acquired a new position in Royalty Pharma plc (NASDAQ:RPRX - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 9,329 shares of the biopharmaceutical company's stock, valued at approximately $238,000.
Other large investors also recently added to or reduced their stakes in the company. Nissay Asset Management Corp Japan ADV raised its holdings in shares of Royalty Pharma by 0.7% in the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 48,481 shares of the biopharmaceutical company's stock valued at $1,238,000 after acquiring an additional 349 shares in the last quarter. Keene & Associates Inc. grew its holdings in shares of Royalty Pharma by 1.9% during the fourth quarter. Keene & Associates Inc. now owns 19,420 shares of the biopharmaceutical company's stock worth $495,000 after purchasing an additional 370 shares in the last quarter. National Bank of Canada FI increased its position in shares of Royalty Pharma by 21.8% in the fourth quarter. National Bank of Canada FI now owns 2,074 shares of the biopharmaceutical company's stock worth $53,000 after purchasing an additional 371 shares during the last quarter. Blue Trust Inc. raised its stake in Royalty Pharma by 31.3% in the fourth quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company's stock valued at $45,000 after purchasing an additional 376 shares in the last quarter. Finally, Sherbrooke Park Advisers LLC raised its stake in Royalty Pharma by 1.1% in the fourth quarter. Sherbrooke Park Advisers LLC now owns 34,891 shares of the biopharmaceutical company's stock valued at $890,000 after purchasing an additional 380 shares in the last quarter. Institutional investors own 54.35% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities analysts have commented on RPRX shares. Citigroup reissued a "buy" rating on shares of Royalty Pharma in a research note on Friday, March 28th. Wall Street Zen lowered shares of Royalty Pharma from a "buy" rating to a "hold" rating in a research report on Tuesday, May 20th. Finally, Morgan Stanley initiated coverage on Royalty Pharma in a research report on Friday, May 16th. They set an "overweight" rating and a $51.00 price target on the stock. Two investment analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $42.50.
Get Our Latest Analysis on RPRX
Royalty Pharma Price Performance
Shares of RPRX stock traded up $0.41 during trading hours on Friday, hitting $33.05. 980,047 shares of the company's stock were exchanged, compared to its average volume of 3,460,201. The company has a market capitalization of $18.58 billion, a PE ratio of 22.78, a PEG ratio of 2.31 and a beta of 0.49. Royalty Pharma plc has a 12-month low of $24.05 and a 12-month high of $34.32. The business's 50 day simple moving average is $32.32 and its 200-day simple moving average is $30.34. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.64.
Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its earnings results on Thursday, May 8th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.99 by $0.07. The company had revenue of $839.00 million for the quarter, compared to analyst estimates of $724.69 million. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. On average, equities research analysts anticipate that Royalty Pharma plc will post 4.49 earnings per share for the current year.
Royalty Pharma Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be paid a $0.22 dividend. This represents a $0.88 annualized dividend and a dividend yield of 2.66%. The ex-dividend date of this dividend is Friday, May 16th. Royalty Pharma's payout ratio is 47.57%.
About Royalty Pharma
(
Free Report)
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
Featured Stories
Before you consider Royalty Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Royalty Pharma wasn't on the list.
While Royalty Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
